Pharma channel feed

CSL's Se­qirus, spurred on by Covid-19 mR­NA vac­cines, props up new unit for 'self-am­pli­fy­ing' shot tech

4 years ago

What an­titrust chal­lenge? Il­lu­mi­na com­pletes $8B Grail buy­out while FTC, EU probes re­main on­go­ing

4 years ago
Deals

We asked our bio­phar­ma read­ers about their com­pa­ny's poli­cies on vac­cine man­dates. Feel­ings are run­ning strong

4 years ago
Startups
Coronavirus

Sack­lers threat­en to walk away from Pur­due opi­oid set­tle­ment as anger builds over im­mu­ni­ty pro­vi­sions — re­port

4 years ago

Still reel­ing from Ze­ju­la set­back, Glax­o­SmithK­line gets a breather with ex­pand­ed PD-1 ap­proval

4 years ago
FDA+

SEC charges for­mer Medi­va­tion ex­ec with in­sid­er trad­ing pri­or to Pfiz­er ac­qui­si­tion

4 years ago
People

Next-gen pso­ri­a­sis drug ri­val­ry be­tween Bris­tol My­ers and Nim­bus spills in­to a le­gal bat­tle

4 years ago
R&D

Eli Lil­ly un­veils a com­plete makeover, erect­ing a neu­ro­science unit cen­tered on Alzheimer's as it uni­fies on­col­o­gy biz

4 years ago

Du­el­ing 7-fig­ure ad cam­paigns set sights on a big drug price ne­go­ti­a­tion bill com­ing soon

4 years ago

End­points News wants to know: Is your com­pa­ny man­dat­ing Covid-19 vac­cines?

4 years ago
Editor's note

Af­ter the long, gru­el­ing path to EUA, Roche says there is a sup­ply short­age of Actem­ra

4 years ago
Coronavirus
Manufacturing

Mer­ck joins its peers with plan to cut ac­cess to dis­count­ed drugs for con­tract phar­ma­cies

4 years ago

Vi­for blasts FDA's 'reck­less' re­nam­ing of 4 drugs un­der the same mol­e­cule moniker

4 years ago
FDA+

New drug ap­pli­ca­tion fil­ings with FDA to cost more than $3M for first time ever in 2022

4 years ago
FDA+

Eli Lil­ly joins the grow­ing ranks of Big Phar­ma play­ers man­dat­ing vac­ci­na­tions for most staffers

4 years ago

First gener­ic com­pe­ti­tion ar­rives for Pfiz­er's megablock­buster an­ti-smok­ing drug

4 years ago
FDA+

Biden's vi­sion for drug pric­ing re­forms: Medicare ne­go­ti­a­tions, penal­ties for prices ris­ing high­er than in­fla­tion

4 years ago

Sen. Rand Paul re­veals his wife bought Gilead stock in Feb­ru­ary 2020 — 16 months af­ter fil­ing dead­line

4 years ago
People

Scoop: VA de­cides against adding Bio­gen's Aduhelm to its for­mu­la­ry as PBM shuns con­tro­ver­sial Alzheimer's drug

4 years ago

FDA re­jects Fi­bro­Gen's ane­mia drug, de­mand­ing an ad­di­tion­al clin­i­cal tri­al

4 years ago
FDA+

BioN­Tech ex­pects to be $18.6B rich­er af­ter this year as Covid boost­ers churn out more da­ta. But it won't change much

4 years ago
Coronavirus

Mod­er­na soars in­to the ranks of the world's top phar­ma play­ers, now worth 3 Re­gen­erons

4 years ago
Bioregnum

Gilead joins the move­ment to man­date staff vac­ci­na­tions against Covid-19. And it looks like the rest of the in­dus­try is fol­low­ing

4 years ago

Ab­b­Vie hands back head­line drug in $63B Al­ler­gan buy­out to Mol­e­c­u­lar Part­ners af­ter FDA re­jec­tion. What's next?

4 years ago
Deals
First page Previous page 234235236237238239240 Next page Last page
A service from the Financial Times